SCHEMBL24309644

SCHEMBL24309644

COCc1ccccc1-c1cc(Oc2ccccc2)nc(NS(=O)(=O)c2cccc(N)c2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.42
▸ PGR P06401 3/20 0.42
▸ TSHR P16473 2/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ PIK3C2B O00750 1/20 0.42
▸ PIK3C2G O75747 1/20 0.42
▸ MAPT P10636 1/20 0.40
▸ HTR6 P50406 1/20 0.37
▸ PLAU P00749 1/20 0.37
▸ F2 P00734 1/20 0.37
▸ PRSS1 P07477 1/20 0.37
▸ PRSS2 P07478 1/20 0.37
▸ PRSS3 P35030 1/20 0.37
▸ GPR39 O43194 1/20 0.37
▸ PRMT1 Q99873 1/20 0.36
▸ KEAP1 Q14145 1/20 0.36
▸ NFE2L2 Q16236 1/20 0.36
▸ ALPL P05186 1/20 0.36
▸ TRIM24 O15164 1/20 0.36
▸ BRD1 O95696 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29566684 1.00 POLB (0.42) POLBPGRTSHRSMN1; SMN2PIK3C2B
SCHEMBL26810769 0.91 TSHR (0.50) PGRTSHRSMN1; SMN2MAPTGPR39
SCHEMBL29566936 0.88 SMN1; SMN2 (0.40) POLBPGRTSHRSMN1; SMN2PIK3C2B
SCHEMBL24310351 0.88 SMN1; SMN2 (0.40) POLBPGRTSHRSMN1; SMN2PIK3C2B
SCHEMBL24309603 0.86 POLB (0.45) POLBPGRTSHRSMN1; SMN2PIK3C2B
SCHEMBL24309297 0.85 PGR (0.52) PGRMAPTF2PRSS1PRSS2
SCHEMBL29567154 0.85 PGR (0.52) PGRMAPTF2PRSS1PRSS2
SCHEMBL29566697 0.85 TSHR (0.38) POLBTSHRSMN1; SMN2PIK3C2BPIK3C2G
SCHEMBL24309704 0.85 TSHR (0.38) POLBTSHRSMN1; SMN2PIK3C2BPIK3C2G
SCHEMBL26806726 0.84 POLB (0.43) POLBPGRTSHRSMN1; SMN2PIK3C2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B POLB 3593/4885PGR 4116/4885TSHR 1755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback